Research Article


DOI :10.26650/IstanbulJPharm.2020.0091   IUP :10.26650/IstanbulJPharm.2020.0091    Full Text (PDF)

Development and validation an HPLC - UV method for determination of esomeprazole and pirfenidone simultaneously in rat plasma: application to a drug monitoring study

Emrah DuralSema Tülay KözSüleyman Köz

Background and Aims: It has been observed that the combined treatment of esomeprazole and pirfenidone provides increased efficacy in the treatment of pulmonary fibrosis disease, recently. The aim of this study is to develop a simple, sensitive, and reliable high-performance liquid chromatography method to be used in drug monitoring to increase the effectiveness of esomeprazole and pirfenidone in treatment and to reduce their adverse effects. Methods: Separation was conducted with a C18 reverse-phase column (4.6 mm x 250 mm, 5 µm) used as a mobile phase prepared with the phosphate buffer (10 mM KH2PO4 and 10 mM K2HPO4) and acetonitrile (60:40, v/v) by an isocratic flow (1 mL/min). Mobile phase pH was adjusted to 3.0. Ultraviolet detection was accomplished at 305 nm. The column oven was held at 35°C to ensure an efficient analytical separation. Results: Analytical recovery of esomeprazole was between 92.43 and 105.36% and for pirfenidone it was found between 89.56 and 104.32%. Accuracy values of esomeprazole and pirfenidone were determined between (-2.90) – 4.22 and (-4.45) – 5.78, respectively. Precision (RSD%) was ≤7.89. The quantification limit was determined as 0.58 and 0.36 ng/mL. Plasma esomeprazole and pirfenidone levels were found as 0.87-8296.87 ng/mL (612.99±2212.20, mean ± standard deviation) and 0.45-238.60 ng/mL (61.44±76.35, mean ± standard deviation), respectively. Conclusion: Unexpectedly high RSD values were observed in both plasma (360.88%) and dose-rated results (89.61%) of esomeprazole, and pirfenidone were thought to be related to individual metabolism differences.


PDF View

References

  • Bodempudi, S.B., Babur, R., & Reddy, K.S. (2015). Development and substantiation of a RP-HPLC method for monitoring of impuri-ties in pirfenidone drug substance. American Journal of Analytical Chemistry, 06(13), 1019-1029. google scholar
  • Çelebi, A., Aydın, D., Kocaman, O., Konduk, B.T., Şentürk, Ö., & Hül-agü, S. (2016). Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastro-esophageal reflux disease. The Turkish Journal of Gastroenterology, 27(5), 408-414. google scholar
  • Eltahir, H.M., & Nazmy, M.H. (2018). Esomeprazole ameliorates CCl4 induced liver fibrosis in rats via modulating oxidative stress, inflammatory, fibrogenic and apoptotic markers. Biomedicine and Pharmacotherapy, 97, 1356-1365. google scholar
  • Estevez, P., Flor, S., Boscolo, O., Tripodi, V., & Lucangioli, S. (2014). Development and validation of a capillary electrophoresis method for determination of enantiomeric purity and related substances of esomeprazole in raw material and pellets. Electro-phoresis, 35(6), 804-810. google scholar
  • Franke, A., Hepp, C., Harder, H., Beglinger, C., & Singer, M. V. (2008). Esomeprazole reduces gastroesophageal reflux after beer con-sumption in healthy volunteers. Scandinavian Journal of Gastro-enterology, 43(12), 1425-1431. google scholar
  • Ghebre, Y.T., & Raghu, G. (2016). Idiopathic pulmonary fibrosis: Novel concepts of proton pump inhibitors as antifibrotic drugs. American Journal of Respiratory and Critical Care Medicine, 193(12), 1345-1352. google scholar
  • Ghebremariam, Y.T., Cooke, J.P., Gerhart, W., Griego, C., Brower, J.B., Doyle-Eisele, M., ... Rosen, G.D. (2015). Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. Journal of Translational Medicine, 13(1), 1-20. google scholar
  • Gopinath, S., Kumar, R.S., Shankar, M.B., & Danabal, P. (2013). De-velopment and validation of a sensitive and high-throughput LC-MS/MS method for the simultaneous determination of esomeprazole and naproxen in human plasma. Biomedical Chro-matography, 27(7), 894-899. google scholar
  • Hodgson, U., Laitinen, T., & Tukiainen, P. (2002). Nationwide preva-lence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax, 57(4), 338-342. google scholar
  • ICH, I. (2005). Q2 (R1): Validation of analytical procedures: Text and methodology. In International Conference on Harmonization, Geneva. google scholar
  • Iyer, S. N., Wild, J. S., Schiedt, M. J., Hyde, D.M., Margolin, S. B., & Giri, S. N. (1995). Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. The Journal of Laboratory and Clinical Medicine, 125(6), 779-785. google scholar
  • Jain, D. K., Jain, N., Charde, R., & Jain, N. (2011). The RP-HPLC meth-od for simultaneous estimation of esomeprazole and naproxen in binary combination. Pharmaceutical Methods, 2(3), 167-172. google scholar
  • Johnson, D. A. (2003). Review of esomeprazole in the treat-ment of acid disorders. Expert Opinion on Pharmacotherapy, 4(2), 253-264. google scholar
  • Kayesh, R., & Sultan, M. Z. (2015). A novel ion-pair RP-HPLC meth-od for simultaneous quantification of naproxen and esomepra-zole in pharmaceutical formulations. Journal of Chromatographic Science, 53(5), 687-693. google scholar
  • Kehrer, J.P., & Margolin, S.B. (1997). Pirfenidone diminishes cyclo-phosphamide-induced lung fibrosis in mice. Toxicology Letters, 90(2-3), 125-132. google scholar
  • Liu, R., Li, P., Xiao, J., Yin, Y., Sun, Z., Bi, K., & Li, Q. (2017). A fast, sensitive, and high throughput method for the determination of esomeprazole in dog plasma by UHPLC-MS/MS: Application to formulation development of the compound preparation of esomeprazole. Journal of Chromatography B: Analytical Technolo-gies in the Biomedical and Life Sciences, 1068-1069, 352-357. google scholar
  • Ma, J., Sun, F., Chen, B., Tu, X., Peng, X., Wen, C. ... Wang, X. (2017). Tissue metabolic changes for effects of pirfenidone in rats of acute paraquat poisoning by GC-MS. Toxicology and Industrial Health, 33(12), 887-900. google scholar
  • Marshall, R.P., Puddicombe, A., Cookson, W.O., & Laurent, G.J. (2000). Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax, 55(2), 143-146. google scholar
  • Mercolini, L., Mandrioli, R., Amore, M., & Raggi, M. A. (2008). Sepa-ration and HPLC analysis of 15 benzodiazepines in human plas-ma. Journal of Separation Science, 31(14), 2619-2626. google scholar
  • More, S., Dalwate, S., Chandramore, N., Jadhav, V., & Jain, A. (2019). Development of chromatographic method and validation for es-timation of pirfenidone in bulk and pharmaceutical dosage form. International Research Journal of Pharmacy, 10(7), 45-50. google scholar
  • Khan, M.M.G., Shirkhedkar, A., Chaudhari, P., & Pawara, P.I. (2019). Analytical techniques for pirfenidone and terizidone: a review. In-ternational Journal of Pharmaceutical Chemistry and Analysis, 6(1), 1-5. google scholar
  • Nadrous, H.F., Myers, J.L., Decker, P.A., & Ryu, J.H. (2005). Idiopathic pulmonary fibrosis in patients younger than 50 years. Mayo Clinic Proceedings, 80(1), 37-40. google scholar
  • Parmar, V.K., Desai, S.B., & Vaja, T. (2014). RP-HPLC and UV spectro-photometric methods for estimation of pirfenidone in pharma-ceutical formulations. Indian Journal of Pharmaceutical Sciences, 76(3), 225-229. google scholar
  • Prabu, S.L., Shirwaikar, A., Shirwaikar, A., Kumar, C.D., Joseph, A., & Kumar, R. (2008). Simultaneous estimation of esomeprazole and domperidone by UV spectrophotometric method. Indian Journal of Pharmaceutical Sciences, 70(1), 128-131. google scholar
  • Raghu, G., Chen, S.-Y., Yeh, W.-S., Maroni, B., Li, Q., Lee, Y.-C., & Col-lard, H. R. (2014). Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. The Lancet. Respiratory Medicine, 2(7), 566-572. google scholar
  • Raman, N.V.V.S.S., Reddy, K.R., Prasad, A.V.S.S., & Ramakrishna, K. (2008). Development and validation of a GC-MS method for the determination of methyl and ethyl camphorsulfonates in esome-prazole magnesium. Chromatographia, 68(7), 675-678. google scholar
  • Ravisankar, P., Anusha Rani, K., Devadasu, C., & Devala Rao, G. (2014). A novel validated RP-HPLC method for the determination of pirfenidone in pharmaceutical dosage forms. Der Pharmacia Lettre, 6(5), 19-29. google scholar
  • Sambhani, N.G., & Biju, V.M.N. (2018). A micelle-enhanced spec-trofluorimetric determination of pirfenidone: application to con-tent uniformity testing and human urine. Journal of Fluorescence, 28(4), 951-957. google scholar
  • Sebaiy, M.M., Hassan, W.S., & Elhennawy, M.E. (2019). Developing a high-performance liquid chromatography (HPLC) method for simultaneous determination of oxytetracycline, tinidazole and esomeprazole in human plasma. Journal of Chromatographic Sci-ence, 57(8), 724-729. google scholar
  • Sotgia, S., Fois, A.G., Sotgiu, E., Zinellu, A., Paliogiannis, P., Mangoni, A.A., & Carru, C. (2020). Micellar electrokinetic capillary chromato-graphic determination of pirfenidone and 5-carboxy-pirfenidone by direct injection of plasma from patients receiving treatment for idiopathic pulmonary fibrosis (IPF). Microchemical Journal, 154, 104536. google scholar
  • Talaat, W. (2017). Bioanalytical method for the estimation of co-administered esomeprazole, leflunomide and ibuprofen in hu-man plasma and in pharmaceutical dosage forms using micellar liquid chromatography. Biomedical Chromatography, 31(5). google scholar
  • Thorat, S.G., Padmane, S.P., Tajne, M.R., & Ittadwar, A.M. (2016). Development and validation of simple, rapid and sensitive UV, HPLC and HPTLC methods for the estimation of pirfenidone in tablet dosage form. Journal of the Chilean Chemical Society, 61(2), 2978-2981. google scholar
  • Tong, S., Wang, X., Jiang, H., Xu, X., Pan, Y., Chen, K. . Hu, G. (2010). Determination of pirfenidone in rat plasma by LC-MS-MS and its application to a pharmacokinetic study. Chromatographia, 71(7), 709-713. google scholar
  • Wang, Y., Zhao, X., Zhong, J., Chen, Y., Liu, X., & Wang, G. (2006). Simple determination of pirfenidone in rat plasma via high-per-formance liquid chromatography. Biomedical Chromatography, 20(12), 1375-1379. google scholar
  • Wen, Y.-G., Liu, X., He, X.-L., Shang, D.-W., Ni, X.-J., Zhang, M. . Qiu, C. (2014). Simultaneous determination of pirfenidone and its metabolite in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. Jour-nal of Analytical Toxicology, 38(9), 645-652. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Dural, E., Köz, S.T., & Köz, S. (2021). Development and validation an HPLC - UV method for determination of esomeprazole and pirfenidone simultaneously in rat plasma: application to a drug monitoring study. İstanbul Journal of Pharmacy, 51(1), 16-25. https://doi.org/10.26650/IstanbulJPharm.2020.0091


AMA

Dural E, Köz S T, Köz S. Development and validation an HPLC - UV method for determination of esomeprazole and pirfenidone simultaneously in rat plasma: application to a drug monitoring study. İstanbul Journal of Pharmacy. 2021;51(1):16-25. https://doi.org/10.26650/IstanbulJPharm.2020.0091


ABNT

Dural, E.; Köz, S.T.; Köz, S. Development and validation an HPLC - UV method for determination of esomeprazole and pirfenidone simultaneously in rat plasma: application to a drug monitoring study. İstanbul Journal of Pharmacy, [Publisher Location], v. 51, n. 1, p. 16-25, 2021.


Chicago: Author-Date Style

Dural, Emrah, and Sema Tülay Köz and Süleyman Köz. 2021. “Development and validation an HPLC - UV method for determination of esomeprazole and pirfenidone simultaneously in rat plasma: application to a drug monitoring study.” İstanbul Journal of Pharmacy 51, no. 1: 16-25. https://doi.org/10.26650/IstanbulJPharm.2020.0091


Chicago: Humanities Style

Dural, Emrah, and Sema Tülay Köz and Süleyman Köz. Development and validation an HPLC - UV method for determination of esomeprazole and pirfenidone simultaneously in rat plasma: application to a drug monitoring study.” İstanbul Journal of Pharmacy 51, no. 1 (Jun. 2021): 16-25. https://doi.org/10.26650/IstanbulJPharm.2020.0091


Harvard: Australian Style

Dural, E & Köz, ST & Köz, S 2021, 'Development and validation an HPLC - UV method for determination of esomeprazole and pirfenidone simultaneously in rat plasma: application to a drug monitoring study', İstanbul Journal of Pharmacy, vol. 51, no. 1, pp. 16-25, viewed 23 Jun. 2021, https://doi.org/10.26650/IstanbulJPharm.2020.0091


Harvard: Author-Date Style

Dural, E. and Köz, S.T. and Köz, S. (2021) ‘Development and validation an HPLC - UV method for determination of esomeprazole and pirfenidone simultaneously in rat plasma: application to a drug monitoring study’, İstanbul Journal of Pharmacy, 51(1), pp. 16-25. https://doi.org/10.26650/IstanbulJPharm.2020.0091 (23 Jun. 2021).


MLA

Dural, Emrah, and Sema Tülay Köz and Süleyman Köz. Development and validation an HPLC - UV method for determination of esomeprazole and pirfenidone simultaneously in rat plasma: application to a drug monitoring study.” İstanbul Journal of Pharmacy, vol. 51, no. 1, 2021, pp. 16-25. [Database Container], https://doi.org/10.26650/IstanbulJPharm.2020.0091


Vancouver

Dural E, Köz ST, Köz S. Development and validation an HPLC - UV method for determination of esomeprazole and pirfenidone simultaneously in rat plasma: application to a drug monitoring study. İstanbul Journal of Pharmacy [Internet]. 23 Jun. 2021 [cited 23 Jun. 2021];51(1):16-25. Available from: https://doi.org/10.26650/IstanbulJPharm.2020.0091 doi: 10.26650/IstanbulJPharm.2020.0091


ISNAD

Dural, Emrah - Köz, SemaTülay - Köz, Süleyman. Development and validation an HPLC - UV method for determination of esomeprazole and pirfenidone simultaneously in rat plasma: application to a drug monitoring study”. İstanbul Journal of Pharmacy 51/1 (Jun. 2021): 16-25. https://doi.org/10.26650/IstanbulJPharm.2020.0091



TIMELINE


Submitted18.09.2020
Accepted21.12.2020
Published Online30.04.2021

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.